Peptide LexiconAll compounds

Endothelin: The 21-Amino-Acid Peptide That Narrows Blood Vessels, and the Six Approved Drugs That Block It

Endothelin-1 is a 21-amino-acid peptide made by the cells lining blood vessels. Its discoverers in 1988 called it one of the most potent vasoconstrictors known. Nobody takes endothelin as a medicine; six approved drugs block its receptors instead. This entry covers the molecule, the three family members and the blocker record.

Endogenous peptideNot a medicine itselfSix approved receptor blockers

Caroline S · Published 2026-11-13

Length

21 amino acids — C109H159N25O32S5, molecular weight 2,491.9 (PubChem CID 16212950)

Sequence

CSCSSLMDKECVYFCHLDIIW (endothelin-1; UniProt P05305, residues 53–73)

Origin

Made by endothelial cells, the lining of blood vessels, from a 212-residue precursor

Last reviewed

2026-11-13

What is it good for?

Endothelin is not something taken for a benefit. It is a signal the body makes that narrows blood vessels, and medicine works by blocking it. Six drugs that block endothelin receptors are approved in the United States — for pulmonary arterial hypertension, for two kidney conditions and for hard-to-control high blood pressure. Endothelin-1 itself is used only as a research tool in small human studies.

Illustration: A coiled molecular model in white and deep green on a white surface with copper accents.
Illustration

What it is

Endothelin-1 is a peptide of 21 amino acids made by endothelial cells, the thin layer lining every blood vessel. Its job is to make vessels narrow. It was isolated and named in 1988 by Yanagisawa and colleagues, whose Nature paper described "an endothelium-derived 21-residue vasoconstrictor peptide" and called it "one of the most potent vasoconstrictors known" (PMID 2451132).

The chain is folded by two disulfide bridges — sulfur-to-sulfur bonds between cysteine residues. UniProt's record for the human precursor (P05305, read 2026-11-13) places them between the first and fifteenth residues and between the third and eleventh (our conversion from the precursor's numbering, positions 53–67 and 55–63).

Property Value Source
Length 21 amino acids UniProt P05305; Yanagisawa 1988
Sequence CSCSSLMDKECVYFCHLDIIW UniProt P05305, residues 53–73
Formula C109H159N25O32S5 PubChem CID 16212950
Molecular weight 2,491.9 PubChem CID 16212950
Precursor 212 residues, with a 17-residue signal piece UniProt P05305
Intermediate Big endothelin-1, 38 residues UniProt P05305

The five sulfur atoms in the formula match the sequence: four cysteines and one methionine (our count).

The three endothelins

A year after the discovery, a second paper showed that humans carry three separate endothelin genes (Inoue et al. 1989, PMID 2649896). Each predicts a 21-residue peptide: the original, now ET-1; ET-2, which differs at two positions; and ET-3, which differs at six. All three raised blood pressure when the synthetic peptides were injected into anaesthetised rats — an animal result.

How it is used in medicine: by being blocked

No one is given endothelin as a treatment. A search of FDA's drug database for endothelin as an active ingredient returned nothing on 2026-11-13; the same search for glucagon returned 12 applications, so the search itself works.

What is approved is a class of drugs that block endothelin's receptors. None is a peptide.

Drug (brand) First US approval Approved for (label, shortened)
Bosentan (Tracleer) 2001-11-20 Pulmonary arterial hypertension
Ambrisentan (Letairis) 2007-06-15 Pulmonary arterial hypertension in adults
Macitentan (Opsumit) 2013-10-18 Pulmonary arterial hypertension in adults
Sparsentan (Filspari) 2023-02-17 IgA nephropathy; focal segmental glomerulosclerosis
Aprocitentan (Tryvio) 2024-03-19 Hypertension not adequately controlled on other drugs
Atrasentan (Vanrafia) 2025-04-02 Proteinuria in IgA nephropathy (accelerated approval)

Dates are the original approvals in Drugs@FDA; indications are from each product's current label in openFDA, both read 2026-11-13. Sparsentan blocks an angiotensin receptor as well; the hormone behind that second target is described in the angiotensin entry.

Two trials show the size of effect behind the first indication. In the bosentan trial of 213 patients, the six-minute walking distance at week 16 was 44 metres better than placebo (95% confidence interval 21 to 67; PMID 11907289). In the macitentan trial of 742 patients, the combined endpoint of death or worsening disease occurred in 46.4% on placebo and 31.4% on the 10 mg dose (PMID 23984728). Both were read as abstracts.

What the labels warn about

Every one of the six labels carries a boxed warning on embryo-fetal toxicity — harm to an unborn child — and is contraindicated in pregnancy. The bosentan and sparsentan labels add a boxed warning on liver toxicity and are supplied only through a restricted programme. The aprocitentan label states that no controlled trial has shown it reduces heart attacks or strokes, and the atrasentan label states that it "has not been established" whether the drug slows the decline of kidney function.

Endothelin itself in human studies

ClinicalTrials.gov returned 58 studies with endothelin-1 named under interventions (2026-11-13). The first results this entry read are studies about endothelin — measuring it in blood, or probing its role in blood flow, as in a 16-person study at the optic nerve in healthy volunteers (NCT00915070) — and one is a trial of the blocker bosentan (NCT00226889). None is a trial of endothelin as a treatment. The 58 records were not all opened, so the count is a ceiling, not a tally of studies that gave the peptide to people.

What is not established

  • Any benefit from taking endothelin. Nothing in the record suggests one, and its known action is to narrow vessels.
  • Whether atrasentan slows kidney decline in IgA nephropathy; its own label says this awaits a confirmatory trial.
  • Whether aprocitentan reduces cardiovascular events; its label says no controlled trial shows it.

Where it stands

  • Endothelin as a product: none approved; none found in FDA's database.
  • Blockers: six approved in the United States, 2001 to 2025.
  • Research record: PubMed 16,708 title records (33,595 mentioning it in title or abstract), 1,097 tagged as randomised controlled trials; ClinicalTrials.gov 363 studies mentioning endothelin (2026-11-13).

The body's vessel-narrowing signals have counterweights: the natriuretic peptides that relax vessels and shed salt, and bradykinin, a short peptide that widens them. Vasopressin, another vessel-constricting hormone, works through different receptors. The 1988 paper noted that parts of endothelin resemble a group of neurotoxins; a peptide toxin in this library is melittin from bee venom.

What the research shows

Narrows blood vessels

Yanagisawa et al. 1988, Nature (PMID 2451132): a 21-residue peptide from endothelial cells, 'one of the most potent vasoconstrictors known'; three human forms shown in 1989 (PMID 2649896)

Blocking its receptors helps in pulmonary arterial hypertension

Bosentan trial, 213 patients: six-minute walk 44 m better than placebo at week 16 (PMID 11907289); macitentan trial, 742 patients: primary endpoint in 46.4% on placebo vs 31.4% on 10 mg (PMID 23984728)

Blocking its receptors helps in the kidney disease IgA nephropathy

Filspari label: indicated to slow kidney function decline in adults with primary IgA nephropathy at risk of progression; Vanrafia label: indicated to reduce proteinuria, an accelerated approval whose label says an effect on kidney function decline is not established

Bars show how much of the evidence is in humans, not how well anything works.

Where it stands

Endothelin as a product

None. FDA's drug database returns no application with endothelin as an active ingredient (openFDA copy dated 2026-11-10; the same search for glucagon returns 12).

Approved blockers

Bosentan 2001, ambrisentan 2007, macitentan 2013, sparsentan 2023, aprocitentan 2024, atrasentan 2025 (Drugs@FDA original approval dates).

Published record

PubMed: 16,708 records with endothelin in the title; 1,097 randomised-trial records mentioning it. ClinicalTrials.gov: 363 studies mention endothelin; 58 list endothelin-1 under interventions (2026-11-13).

Frequently asked questions

What is endothelin?

A family of three 21-amino-acid peptides made in the body. Endothelin-1, the main one, is produced by the cells lining blood vessels and makes vessels narrow.

What does endothelin do?

It constricts blood vessels and so raises blood pressure. The 1988 paper that first described it called it one of the most potent vasoconstrictors known.

Is endothelin a peptide?

Yes. Endothelin-1 is a single chain of 21 amino acids folded by two disulfide bridges. It is cut from a much longer 212-residue precursor protein.

Can endothelin be taken as a medicine or supplement?

No approved product contains it. FDA's drug database lists no application with endothelin as an active ingredient. Medicine uses drugs that block its receptors.

What are endothelin receptor antagonists?

Drugs that stop endothelin acting on its receptors. Six are approved in the United States: bosentan, ambrisentan, macitentan, sparsentan, aprocitentan and atrasentan. None of them is a peptide.

What is big endothelin?

The 38-residue intermediate that is cut once more to release the active 21-residue endothelin-1. UniProt lists it as 'Big endothelin-1'.